Baird analyst David Rescott raised the firm’s price target on Boston Scientific to $91 from $90 and keeps an Outperform rating on the shares. The firm said it remains their top idea after Q2 delivered another beat/raise as top-line growth accelerated and adj EPS maintained +15% year-over-year growth, with the first full quarter of US Farapulse driving $110M of upside versus estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific raises FY24 adjusted EPS view to $2.38-$2.42 from $2.29-$2.34
- Boston Scientific sees Q3 EPS 57c-59c, consensus 57c
- Boston Scientific reports Q2 adjusted EPS 62c, consensus 58c
- Boston Scientific Announces Results for Second Quarter 2024
- Notable companies reporting before tomorrow’s open